TY - JOUR
T1 - Effects of repeated dosing with Udenafil (Zydena) on cognition, somatization and erection in patients with erectile dysfunction
T2 - A pilot study
AU - Shim, Y. S.
AU - Pae, C. U.
AU - Kim, S. W.
AU - Kim, H. W.
AU - Kim, J. C.
AU - Koh, J. S.
PY - 2011/5
Y1 - 2011/5
N2 - The PDE5 inhibitors have recently been found to have cognitive-enhancing effects in animal models. To investigate the efficacy of repeated dosing with a PDE5 inhibitor on cognitive function and somatization in patients with erectile dysfunction, 27 patients with erectile dysfunction received udenafil (100 mg) at 3-day intervals for 2 months. The international index of erectile function-5 (IIEF-5), a cognitive battery (the Korean version of mini-mental state examination (K-MMSE), the frontal assessment battery (K-FAB), the Seoul verbal learning test) and a physical health questionnaire-15 (PHQ-15) were performed at baseline and at 2 months, following the administration of udenafil. The patients were divided on the basis of their IIEF-5 score into responders (change7) and non-responders. The mean IIEF-5 score was significantly increased after treatment (7.92±3.83 to 16.33±4.75, P<0.001). The scores of K-MMSE (27.03±1.58 to 28.07±1.57, P = 0.001), K-FAB (13.65±1.96 to 15.41±1.85, P<0.001) and PHQ-15 (18.92±4.96 to 17.63±4.75, P = 0.003) were significantly improved after treatment. In addition, the responders (n = 16) had more improved cognitive function (r = 0.603, P = 0.001) and somatization (r = 0.402, P = 0.038) than non-responders (n = 11). Repeated dosing with a PDE5 inhibitor seems to improve cognitive function and somatization, as well as erectile function in patients with erectile dysfunction.
AB - The PDE5 inhibitors have recently been found to have cognitive-enhancing effects in animal models. To investigate the efficacy of repeated dosing with a PDE5 inhibitor on cognitive function and somatization in patients with erectile dysfunction, 27 patients with erectile dysfunction received udenafil (100 mg) at 3-day intervals for 2 months. The international index of erectile function-5 (IIEF-5), a cognitive battery (the Korean version of mini-mental state examination (K-MMSE), the frontal assessment battery (K-FAB), the Seoul verbal learning test) and a physical health questionnaire-15 (PHQ-15) were performed at baseline and at 2 months, following the administration of udenafil. The patients were divided on the basis of their IIEF-5 score into responders (change7) and non-responders. The mean IIEF-5 score was significantly increased after treatment (7.92±3.83 to 16.33±4.75, P<0.001). The scores of K-MMSE (27.03±1.58 to 28.07±1.57, P = 0.001), K-FAB (13.65±1.96 to 15.41±1.85, P<0.001) and PHQ-15 (18.92±4.96 to 17.63±4.75, P = 0.003) were significantly improved after treatment. In addition, the responders (n = 16) had more improved cognitive function (r = 0.603, P = 0.001) and somatization (r = 0.402, P = 0.038) than non-responders (n = 11). Repeated dosing with a PDE5 inhibitor seems to improve cognitive function and somatization, as well as erectile function in patients with erectile dysfunction.
KW - PDE5 inhibitor
KW - cognition
KW - erectile dysfunction
KW - somatization disorder
UR - https://www.scopus.com/pages/publications/79959268066
U2 - 10.1038/ijir.2011.13
DO - 10.1038/ijir.2011.13
M3 - Article
C2 - 21544084
AN - SCOPUS:79959268066
SN - 0955-9930
VL - 23
SP - 109
EP - 114
JO - International Journal of Impotence Research
JF - International Journal of Impotence Research
IS - 3
ER -